| 前收市價 | 123.75 |
| 開市 | 123.30 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 121.85 - 125.15 |
| 52 週波幅 | 65.40 - 125.20 |
| 成交量 | |
| 平均成交量 | 308,128 |
| 市值 | 23.741B |
| Beta 值 (5 年，每月) | 0.40 |
| 市盈率 (最近 12 個月) | 70.77 |
| 每股盈利 (最近 12 個月) | 1.76 |
| 業績公佈日 | 2024年7月24日 - 2024年8月03日 |
| 遠期股息及收益率 | 1.36 (1.09%) |
| 除息日 | 2024年4月26日 |
| 1 年預測目標價 | 125.90 |
Insider Monkey20 Most Valuable Belgian Companies in 2024
In this article, we will be looking at the 20 most valuable Belgian companies in 2024. If you wish to skip our detailed analysis, you can move directly to the 5 Most Valuable Belgian Companies in 2024. Economy of Belgium: An Analysis Belgium has a small and open economy which recorded a GDP worth $627.51 […]
BenzingaFDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. The company says Rystiggo is the only FDA-approved treatment in adults for anti-AChR and anti-MuSK antibody-positive gMG, the two most common subtypes of gMG. The FDA approval is supported by safety and efficacy data from the pivotal Phase 3 Mycarin
